BRIEF: Ascletis raises $107 million to fund obesity drug trials
Ascletis Pharma Inc. (1672.HK) saidon Tuesday that it raised about HK$835 million ($107 million) by selling 69.26 million new shares in a placement at HK$12.18 each. The placement price represents…
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
